In addition to the clinical trials mentioned above, the clinical and preclinical study of new therapeutic radioisotopes (i.e., alpha emitters), new vector molecules targeting PSMA or other targets will point to future breakthroughs in prostate cancer radionuclide therapy. Here, FOLH1 is linked to prostate carcinoma.